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Glutathione transferases (GST) are essentially known as enzymes that catalyse the conjugation of glutathione to various
electrophilic compounds such as chemical carcinogens, environmental pollutants, and antitumor agents. However, this protein
family is also involved in the metabolism of endogenous compounds which play critical roles in the regulation of signaling
pathways. For example, the lipid peroxidation product 4-hydroxynonenal (4-HNE) and the prostaglandin 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2) are metabolized by GSTs and these compounds are known to influence the activity of transcription
factors and protein kinases involved in stress response, proliferation, diﬀerentiation, or apoptosis. Furthermore, several studies
have demonstrated that GSTs are able to interact with diﬀerent protein partners such as mitogen activated protein kinases (i.e.,
c-jun N-terminal kinase (JNK) and apoptosis signal-regulating kinase 1 (ASK1)) which are also involved in cell signaling. New
functions of GSTs, including S-glutathionylation of proteins by GSTs and ability to be a nitric oxide (NO) carrier have also been
described. Taken together, these observations strongly suggest that GST might play a crucial role during normal or cancer cells
proliferation or apoptosis.
1. Introduction
Glutathione transferases (GSTs) represent a major cellular
defence system; they constitute a multigene family divided
in seven families (Alpha, Mu, Pi, Theta, Sigma, Zeta,
and Omega) with functions ranging from detoxification to
biosynthesis and cell signaling [1, 2]. The most extensively
investigated role of GSTs is their function of detoxification
enzymes, where they catalyse the nucleophilic attack of glu-
tathione (GSH) on electrophilic substrates. This mechanism
allowed to protect a variety of cell components (protein,
lipid, DNA) against reactive molecules such as electrophilic
metabolites formed after xenobiotics phase I metabolism or
endogenous α,β-unsaturated aldehydes and hydroperoxides
formed as secondary metabolites during oxidative stress.
GSTs are also involved in metabolism of endogenous
lipid mediators which influence diverse-signaling pathways.
Among them, the 15-deoxy-Δ12,14-prostaglandin J2 (15d-
PGJ2) regulates the activity of three transcription factors
playing a central role in stress response, diﬀerentiation and
proliferation: the peroxisome proliferator-activated recep-
tor γ (PPARγ), the nuclear factor-erythroid 2 p45-related
factor 2 (Nrf2), and the nuclear factor κB (NF-κB) [2].
Another one, the endogenous lipid peroxidation product
4-hydroxynonenal (4-HNE) is also believed to act as an
intracellular signaling molecule [3]. Therefore, its conjuga-
tion with glutathione by GSTs will influence a number of
pathways. Indeed, like 15d-PGJ2, 4-HNE can stimulate gene
expression through Nrf2 and prevent activation of NF-κB by
inhibiting IκB phosphorylation. It has also been reported to
modulate several cell-surface receptors, to activate epithelial
growth factor receptor and platelet-derived growth factor-
β receptor, and to upregulate transforming growth factor
receptor β1 [4]. Altogether, these observations suggest
that GSTs, which are involved in 4-HNE and 15d-PGJ2
metabolism, will certainly influence many signal transduc-
tion pathways and modulate cell survival and proliferation.
During the last decade, research on GSTs has unravelled
yet another major function, namely a role in regulating
cellular signaling by forming protein-protein interactions
with critical proteins involved in controlling stress response,
apoptosis, and proliferation. For example, the ligand-binding
capacity of GST results in the negative regulation of sig-
naling pathways through sequestration of protein kinases.
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Adler et al. [5] published the first study showing that mouse
GSTpi interacts with the protein kinase c-jun N-terminal
kinase (JNK). Dissociation of this complex by diﬀerent types
of stress leads to the activation of JNK and phosphorylation
of its substrate, the transcription factor c-jun. Thereafter,
other interactions have been identified and their implication
in regulation of diﬀerent biological processes has been
demonstrated.
Another interesting function of GST, and especially of
GSTPi, involved the regulation of a posttranslational mod-
ification of proteins, the S-glutathionylation and its impli-
cation in the protection against oxidative damage and the
control of the redox signaling pathway. S-glutathionylation
is characterized by the conjugation of GSH to low-cysteine
sulfydryl or sulfonic-acid moieties in target proteins. Several
studies have shown that various intermediates of signaling
pathways controlling the survival/apoptosis mechanisms
(p53, caspase 3,. . .) could be S-glutathionylated [6, 7].
Interestingly, these modifications seemed to modulate their
activities.
Last, but not least, a thrilling new concept of NO stockage
by GSTs have been brought up [8]. Indeed, several GSTs,
and especially GSTP1-1, could bind NO under dinitrosyl
iron complexes (DNICs). This binding seems to protect
cells against high levels of DNICs, which are known to
inhibit glutathione reductase, and to limit the peroxinitrite
formation [9].
Taken together, these observations strongly suggest that
GST might play a crucial role during normal, or cancer-cells
proliferation or apoptosis. In this paper, we will focus on
the major findings regarding the diﬀerent modes of action
of GST to regulate cell signaling, and we will give some
examples demonstrating the involvement of GSTs in the
regulation of hepatocyte proliferation and apoptosis.
2. 4-HNE, Cell Signaling, and GSTA4
4-HNE is a major product of the lipid peroxidation
process that is characterized by peroxidative decomposition
of polyunsaturated lipids. The mitogen-activated protein
kinase (MAPK) pathways involved in cellular stress responses
appear to be particularly sensitive to 4-HNE [4]. Indeed,
the ability of 4-HNE to initiate increases in tyrosine phos-
phorylation is involved in the activation of c-jun N-terminal
kinases (JNK) and p38 [10]. Both of them can regulate
several transcription factors involved in cellular responses
including cell proliferation, inflammatory responses,
proteasome-mediated protein degradation and apoptosis.
Many studies underlined concentration-dependent eﬀect of
4-HNE on cell signaling pathways. A moderately high con-
centration of 4-HNE can induce apoptosis, diﬀerentiation,
and aﬀect activation of adenylate cyclase, JNK, protein kinase
C, and caspase 3 [11, 12]. In contrast, a low concentration
of 4-HNE can induce cell proliferation. Another study
confirmed that 4-HNE has a dose-dependent eﬀect, and
a distinction could be made between a supraphysiological
concentration (100 μM), which was primarily cytotoxic and
a physiological range (below 10 μM) modulating cell growth
[13]. These eﬀects consist in a transient inhibition of the
initial phase of cell growth, which under optimal conditions
(in presence of serum) was followed by a period of increased
proliferation, compared to untreated control cultures, until
confluence was attained [13].
4-HNE also inhibits the expression of cyclin D1, D2
and A and, consequently, the activity of cyclin-dependent
kinase 4/6 (Cdk4/6) and Cdk2 [14]. Interestingly, these Cdk-
cyclin complexes are involved in the phosphorylation of
retinoblastoma proteins, and therefore their partial inactiva-
tion, allowing the transcription of E2F-controlled genes and
the progression in S phase. Moreover, 4-HNE upregulates
the expression of p21waf1 which is involved in the negative
regulation of cyclin-Cdk complex protein kinase activities
[15]. These findings show that 4-HNE can orchestrate the
simultaneous expression of many diﬀerent genes involved in
the control of cell proliferation [16].
These observations clearly demonstrate that 4-HNE
intracellular amount must be tightly controlled to prevent
cellular damages and/or to regulate stress-response signaling.
Although diﬀerent enzymes such as alcohol dehydrogenase,
aldolase reductase, or aldehyde dehydrogenase are involved
in the metabolism of 4-HNE, the majority of 4-HNE is
metabolized by GST, via its conjugation to GSH, which
promotes its detoxification [18, 19]. In the liver, Kupﬀer
and stellate cells have the capacity to metabolize 4-HNE,
but to varying degrees compared to hepatocytes (100 times
less eﬃciently for Kupﬀer cells than hepatocytes). The main
GST involved in 4-HNE detoxification is GSTA4 [20, 21].
Interestingly, mGSTA4 was induced in vivo and in cultured
hepatocytes by tumor necrosis factor α (TNFα), interleukin-
6 (IL-6), and epidermal growth factor (EGF) [22]. All these
factors that play crucial roles in hepatocyte survival and
proliferation during liver regeneration. Moreover, mGsta4
gene expression was increased at 1 and 24 hour post-
partial hepatectomy (PH) compared with normal and sham-
operated animals while a 3-fold increase in 4-HNE levels was
observed 1 hour after PH [22].
Altogether, these studies demonstrate that the intracellu-
lar concentration of 4-HNE appears to be crucial for cell cycle
signaling and may be a determinant for the signaling during
diﬀerentiation, proliferation, transformation, or apoptosis.
Importantly, the intracellular concentrations of 4-HNE are
regulated by the action of GSTA4-4, which conjugates 4-HNE
to GSH.
3. Modulation of 15d-PGJ2 Signaling
Pathway by GST
Prostaglandins (PG) are lipid compounds enzymatically
derived from arachidonic acid that is released from the cell
membrane phospholipids by phospholipase A2. Arachidonic
acid is first metabolized by cyclooxygenase in PGG2, which
in turn is transformed in PGH2 by PGH2 synthase. PGH2 is
then conversed in other prostagladins (PGE2, PGF2α, PGI2,
thromboxanes, PGD2) by several specific synthases. These
mediators are autocrine or paracrine molecules with local
activities and involved a large panel of functions including
inflammation, neuronal plasticity, and platelet aggregation.
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Some of them (PGE2, PGD2, and PGF2α) are secreted and
act by binding to a plasma membrane receptor.
Among the prostaglandin species, 15-deoxy-Δ12−14
prostaglandin J2 (15d-PGJ2) is a downstream metabolite
of PGD2 that acts by binding to intracellular receptors or
transcription factors (Figure 1) [23]. Indeed, this compound
owns an electrophilic α,β-unsaturated carbonyl group in
its cyclopentenone ring, which can interact with cellular
nucleophile groups such as thiols present in glutathione
or cysteine. 15d-PGJ2 biological eﬀects are multiple. For
example, it is a natural activating ligand of PPARγ [24].
After activation, PPARγ is heterodimerized with Retinoid X
Receptor (RXR) leading to the induction of PPRE-driven
gene expression. In the liver, the level of PPARγ is low,
however it is implicated in several pathologies and its
activation leads to a diminution of hepatocellular cancer
growth by induction of cell apoptosis [25, 26]. Interestingly,
binding of 15d-PGJ2 to PPARγ in mouse liver results in the
induction of hepatocyte growh factor (HGF) [27] and HGF
induction is known to increase apoptosis and to decrease
DNA synthesis in HepG2 [28]. A recent study has also
linked the antineoplastic role of 15d-PGJ2 in the HBV-
associated HCC (Hepatitis B Virus-associated Hepatocellular
Carcinoma) growth and the activation of PPARγ [29].
Furthermore, two diﬀerent studies have suggested a
potential role of 15d-PGJ2 in hepatic cell proliferation.
Cheng et al. [30] reported that the 15d-PGJ2 was involved in
the growth, cell cycle, and diﬀerentiation of hepatic oval cells,
raising the possibility that the PPARγ ligands may regulate
liver regeneration and hepatocarcinogenesis. In a second
study, Yamamoto et al. [31] demonstrated that, during rat
liver regeneration, the number of PPARγ-stained hepatocytes
decreased 24 h after partial hepatectomy and increased in
the late phase of liver regeneration compared to the sham-
operated group.Moreover, the peaks of serum 15d-PGJ2 level
and hepatic PPARγ expression coincided with the late phase
of liver regeneration [31]. These authors concluded that the
PPARγ/15d-PGJ2 system may be one of the key negative
regulators of hepatocyte proliferation andmay be responsible
for the inhibition of liver growth in the late phase of liver
regeneration.
15d-PGJ2 has also been shown to inhibit the NF-κB
signaling pathway [32]. In cells, NFκB is associated with
IκB proteins in the cytoplasm in an inactive complex. After
proinflammatory or growth factor stimuli, phosphorylation
of IκB by IκB kinase (IKK) leads to its proteasomal
degradation. These conditions allow the release of NF-κB, its
phosphorylation and its translocation in the nucleus where,
alone or in combination with other transcription factors, it
induces target gene expression [33, 34]. The role of NF-κB in
controlling cell cycle regulators, and more particularly cyclin
D1, has been observed in investigations that used the IκB
“super repressor” in order to inhibit NF-κB activity [35].
These findings suggest an important role for NF-κB in the
regulation of cell cycle. Furthermore, NF-κB with upstream
participation of TNFα, signaling through TNF receptor 1
(TNFR1) together with IL-6 and signal transducers and
activators of transcription 3 (STAT3) is required for initiation
of liver regeneration [36]. Several studies have shown that
15d-PGJ2 is able to inhibit the NF-κB, targeting IKK by
a covalent binding on a cysteine 179 (Cys-179) [32, 37].
15d-PGJ2 also directly inhibits binding of NF-κB to DNA-
specific sequences by modifying the NF-κB Cys-38 [32].
Furthermore, Okano et al. [38] have observed that 15d-
PGJ2 suppressed NF-κB activation through independent
PPARγ mechanisms in a hepatic cell line (SK-Hep1 cells).
Interestingly, the same eﬀects were observed in HepG2 cells,
however, in this cell line the mechanism seems to involve the
PPARγ activation.
15d-PGJ2 can also stimulate Nrf2-mediated induction of
gene expression through the antioxidant response element
[39, 40]. Indeed, 15d-PGJ2 is able to modify cysteine residues
in the cytoskeleton-associated protein Keap1 (Kelchlike
ECH-associated protein 1), and thus overcomes the ability
of Keap1 to target Nrf2 for proteasomal degradation [41].
Therefore, conjugation of 15d-PGJ2 with GSH abolishes its
ability to modify Keap1. The regulation of Nrf2 by 15d-PGJ2
might have important consequences in liver regeneration.
Indeed, Beyer et al. [42] demonstrated impaired liver
regeneration in Nrf2 knockout mice and revealed novel roles
of Nrf2 in the regulation of growth factor signaling and in
tissue repair. The same group showed that Nrf2 controls
insulin receptor signaling in the regenerating liver [43].
Finally, a recent work has demonstrated that Nrf2 recognized
a functional ARE (antioxidant responsive element) in the
promoter of Notch1 that regulates processes such as prolif-
eration and cell-fate decisions [39]. In this study, the authors
have reported a functional role for this cross talk between
the two pathways and show a delayed liver regeneration after
partial hepatectomy in Nrf2 knockout mice that was rescued
by reestablishment of Notch1 signaling. Taken together, these
studies suggest that 15d-PGJ2 could also modulate liver
regeneration through the regulation of Nrf2.
Diﬀerent studies have shown that GSTs are able to reg-
ulate the level of 15d-PGJ2. Indeed, GSTs play a critical role
at several levels in the synthesis and the degradation of this
compound. GSTS1 has been identified as the prostaglandin
synthase implicated in the production of PGD2 (Figure 1),
the metabolic precursor of 15d-PGJ2 [44]. On the other
hand, GSTA1, GSTM1, and GSTP1 have been shown to
catalyze the conjugation of PGJ2 with glutathione [45]. This
conjugate is then eliminated by the MRP (Multidrug Resis-
tance Protein) transporter. 15d-PGJ2 is also metabolized via
conjugation with glutathione in HepG2 cells [46], however,
this conjugation can be observed in presence or absence of
GST suggesting that the level of GSH in cell could modulate
the action of 15d-PGJ2 [47]. Kawamoto et al. [48] have
observed that 15d-PGJ2 is able to induce the GSTP1 in the
R34 rat liver epithelial cell line through binding of diﬀerent
proteins, including c-jun, to a responsive element present in
the GSTP1 5′-flanking region. On the other hand, 15d-PGJ2
is able to directly posttraductionally modify GSTP1 to inhibit
its activity. This covalent binding implicates alkylation of
the Cys-47 and/or 101 [49]. Since GSTP1 is overexpressed
in tumor cells and might be involved in anticancer drug
resistance, 15d-PGJ2 binding to GSTP1 could lead to the
development of irreversible inhibitors in anticancer therapy.
Interestingly, the binding or sequestration of 15d-PGJ2 to
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Figure 1: The prostaglandin biosynthetic pathway (adapted from [1]) 15-deoxyΔ12−14-PGJ2 is a metabolite derived from arachidonic
acid. Several GSTs are implicated in the regulation of its formation: GSTS1 metabolized PGH2 in PGD2; GSTA1, GSTM1, and GSTP1
conjugated GSH to PGJ2 and 15-deoxyΔ12−14-PGJ2. This conjugation led to the regulation of various transcription factors (PPARγ, NF-κB,
and Nrf2).
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Figure 2: Scheme of the various interactions between GSTs and MAPK implicated in stress-signaling pathway (adapted from [17]). The
mitogen-activated protein kinase (MAPK) family is composed of three types of kinases: MAP3K, MAP2K, and MAPK. In mammal, 3 major
subgroups of MAPK are found: ERK, JNK, and p38. ERK is activated by proliferation and diﬀerentiation stimuli whereas JNK and p38
are preferentially activated by environmental stress. Upstream kinases (MAP3K, MAP2K) initiate activation of MAPK cascade in response
to environmental changes and MAPK phosphorylate downstream targets such as transcription factors and generate appropriate biological
response. Several GSTs are able to interact with various of these MAPK in nonstress conditions. Environmental stress leads to the disruption
of these interactions and the activation of the signaling pathway. ROS: reactive oxygen species; UV: ultraviolet; ER: endoplasmic reticulum;
TRAF2; TNF-receptor-associated factor 2; ASK1: apoptosis signal-regulating kinase 1; MEKK1: Mitogen-activated protein kinase kinase
kinase 1; JNK: c-Jun N-terminal kinase 1; ERK: extracellular regulated kinase.
GST is also observed with GSTM1a and GSTA1 and inhibits
the transactivation of PPARγ [50]. The ability of diﬀerent
GSTs to aﬀect either synthesis, or elimination of 15d-PGJ2
places GSTs as central regulators in cell signaling mediated
by this eicosanoid.
4. GST-Protein Interactions and
Cell Signaling
Cells are continuously exposed to external or internal stress
which trigger signaling pathways and lead to the activation
of several biological processes such as cell proliferation,
diﬀerentiation, apoptosis or stress response. Control of
these diﬀerent pathways involves upstream activation of
three protein kinase families: MAP3K, MAP2K and MAPK.
Regulation of these protein kinases is complex and the
existence of stress sensors. In the last decade, literature
brought up the idea that GSTs could play such a role
(Figure 2).
The first evidence for a direct interaction of a GST with
another protein has been published by Adler et al. [5]. In this
study, the authors demonstrated that mouse Gstpi interacts
with JNK in mice 3T3/4A fibroblasts. Under a monomeric
state, Gstpi acts as a direct JNK inhibitor in nonstressed
cells by forming a complex with JNK and c-jun. Oxidative
stress (UV, H2O2, etc.) induces the dimerization of GSTpi
and activation of c-jun through its phosphorylation on
Ser-63 and Ser-73 residues. Residues 194 to 201 (sequence
SSPEHVNR) of Gstpi [4] and the C-terminal region of JNK
[51] seem to be implicate in this interaction.
Subsequently, several other studies have corroborated
this model. For example, Bernardini et al. [52] analyzed the
correlation between the modulation of the GSTP1 expres-
sion, its dimerization and its catalytic activity following
treatment of human leukemia Jurkat cells with agents known
to induce apoptosis through a JNK-dependent signaling
pathway. Results have shown that hydrogen peroxide (H2O2)
and, to a lesser extent, etoposide lead to the activation
of JNK pathway. This process was concomitant to the
apparition of dimerized forms of GSTP1 owning disulphide
bound between their Cys-47 and monomeric forms owning
intrasubunit disulphide bound between Cys-47 and Cys-
101. Furthermore, this dimerization is responsible for an
inhibition of the GST activity which could be explained
by the localization of these cysteines in the glutathione-
binding domain of GSTP1. However, in a recent work,
Gildenhuys et al. [53] have criticized this model. Indeed,
using equilibrium folding and unfolding kinetic experiments
as well as molecular modelling they brought the demonstra-
tion that binding with JNK involved the dimeric form of
GSTP1-1. Thus, further works are necessary to determine the
real mechanisms involved in these interactions. On the other
hand, understanding of these processes is also complicated
by the fact that diﬀerent haplotypes of GSTP1 triggered
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diﬀerent eﬀects. Indeed, two common functional variants
of GSTP1 have been identified at amino 105 (Ile-Val) and
114 (Ala-Val). These variants lead to the existence of four
haplotypes: the wild type GSTP1∗A (Ile105 + Ala114), and
three variants GSTP1∗B (Val105 + Ala114), GSTP1∗C (val105
+ Val114) and GSTP1∗D (Ile105 + Val114). GSTP1∗A has been
shown to be able to slowdown cell’s proliferation whereas
the GSTP1∗C haplotype had no impact on this endpoint
[54]. Furthermore, GSTP1∗A seems to be able to protect
cells from apoptosis through a JNK-independent pathway
while for GSTP1∗C this eﬀect seems to be JNK dependent
[54]. More recently, The´venin et al. [55], have observed a
higher inhibitory eﬀect of GSTP1∗C on the phosphorylated
isoforms JNK 1 and 2 compared to GSTP1∗A suggesting
that these interactions depend on the activation’s state
of JNK. They have also demonstrated that interaction of
phosphorylated JNK is enhanced in presence of ATF2,
another substrate of JNK involved in oncogenesis, and that
ATF2 is needed for the interaction of inactived JNK with
GSTP1.
In vivo studies have also been performed and shown
that in GSTpi−/− mice, JNK activity is constitutively
enhanced, at least in liver, lung, and fibroblasts, and that,
in such conditions, JNK-signalling pathway is upregulated
triggering an increase in AP-1 DNA binding and HO-1
mRNA expression [56]. More recently, Castro-Caldas et al.
[57] have observed, in a mouse Parkinson’s disease model
induced by a neurotoxin, that GSTpi−/− mice are more
sentitive than wild-type mice to this stress. Indeed, in the
midbrain and in the striatum, GSTpi seems to play the role
of an endogenous regluator of the JNK signalling pathway by
directly interacting with JNK.
Noteworthy, the direct interaction of JNK with GSTs
is not limited to the GSTPi family. Indeed, Romero et al.
[58] have shown that GSTA1 interacts physically with JNK
in caco-2 cells. They showed that GSTA1 levels were lower
in preconfluent cells than in postconfluent cells and they
observed that response of caco-2 cells to a sodium butyrate
JNK-dependent apoptotic stimulus was more important
in preconfluent cells. In a diﬀerent study, Desmots et al.
[59] have established a correlation between phosphoryla-
tion of JNK and mGSTA4 upregulation under oxidative
stress conditions and demonstrated that mouse GSTA4 and
JNK coimmunoprecipitate in liver tissue extracts suggesting
that mGSTA4 might be also an endogenous regulator of
JNK activity by direct binding. Furthermore, these authors
showed that hepatic mGSTA4 is strongly increased dur-
ing oxidative stress possibly via JNK pathway and during
proliferation via MEK/extracellular signal-regulated kinase
pathway.
In 2001, Cho et al. [60] have shown by yeast two-
hybrid technology that mouse GSTM1-1 is able to interact
directly with ASK1, a protein kinase belonging to theMAP3K
family. This interaction inhibits apoptosis signal regulated
kinase 1 (ASK1)-mediated activation of JNK/SAPK signaling
pathway induced by several stress stimuli such as H2O2 or
UV when GSTM1-1 is overexpressed in cells. Therefore,
it was suggested that GSTM1-1 has a role as an ASK1-
repressor under unstimulated conditions. Furthermore, this
role seems to be independent of the GST activity since
mutant GSTM1-1 lacking catalytic activity also represses
ASK1. The involvement of the C-terminal region of GSTM1-
1 and N-terminal region of ASK1 in this interaction has been
determined using truncated proteins [60]. Intriguingly, the
same region of ASK1 interacts with thioredoxin (Trx) and
it has been shown that, depending on the type of stress,
ASK1 dissociates from GST or Trx suggesting the presence
of a pool of ASK1-GSTM1-1 and ASK1-Trx complexes
under unstressed conditions. Indeed, Dorion et al. [61] have
observed that heat shock is able to disrupt the interaction
between ASK1 and GSTM1 leading to the heat-shock-
mediated p38 signaling activation, whereas no dissociations
were observed between ASK1 and Trx under the same
conditions. Furthermore, they observed that ROS exhibited
the opposite eﬀect, triggering dissociation between ASK1 and
Trx with an activation of the p38 oxidative stress sensing
pathway without any eﬀect on the ASK1-GSTM1 complexes.
Interestingly, Gilot et al. [62] have suggested that not only
GSTM1, but also GSTA1 and GSTP1, could play a key role in
regulation of ASK1 protein kinase activity in rat hepatocytes
and thus on apoptosis.
GSTP1 is also able to block ASK1 activation by inter-
acting physically with the Tumor necrosis factor receptor
associated factor 2 (TRAF2) [63]. TRAF proteins associate
with, and mediate the signal transduction from, members
of the TNF receptor superfamily. For example, binding
of TNFα on its receptors, TNF Receptor 1 or 2, leads
to the homotypic aggregation of these receptors which
results in the recruitment of several adaptors in the receptor
cytoplasmic N-terminal domain. Among these adaptors,
TNF-R1 associated death domain (TRADD) is able to
recruit TRAF2 after TNFα-activation of TNF-Receptor 1,
while a direct association between TNF-Receptor 2 and
TRAF2 is observed. These interactions trigger activation
of JNK and p38 signal pathways by a dissociation of the
ASK1-Trx complex. Wu et al. [63] demonstrated that the
binding of GSTP1 and TRAF2 triggers the suppression of
TNFα-TRAF2-ASK1 signaling pathway activation. Similarly
to the other interactions described previously, the activity of
GSTP1 is not necessary for this binding, and the interaction
between GSTP1 and TRAF2 is observed only in unstimulated
cells.
Many other studies have confirmed the involvement of
GSTs in cell signaling without performing direct-binding
experiments: Ishisaki et al. [64] have shown that increasing
expression in GSTP1 protects against dopamine-induced
apoptosis in dopaminergic neurons by decreasing JNK
activity; Elsby et al. [56] have demonstrated an increase in
the constitutive JNK signaling in mice lacking GSTpi; and
overexpression of hGSTA2-2 protects against apoptosis in
K562 cells [65]. More recently, Piaggi et al. [66] suggested
that overexpression of GSTO1-1 is associated with activation
of survival pathway (Akt, ERK1/2) and inhibition of apop-
totic signaling (JNK) as well as protection against cisplatin-
induced apoptosis. Among these studies, experiments done
by Yin et al. [67] are particularly striking. Using a GSTPi
inducible expression vector in 3T3 cells, they have shown
that GSTpi allows protection against H2O2-induced cell
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death by coordinating an ERK/p38/IKK activation and a JNK
suppression.
5. S-Glutathionylation
S-glutathionylation is a posttranslational modification of
proteins characterized by the conjugation of GSH to a low
pKa cysteine residues allowing a protection against oxidative
stress. Even if in vitro studies have underlined that this
process occurs spontaneously, several studies have shown
that GSTPi could influence the rate of this reaction [68–70].
Thus, Townsend et al. [68] have observed that, under stress
conditions, GSTPi can mediate a self S-glutathionylation
on its Cys-47 and Cys-101 and that these modifications
by interfering with the GSTPi/JNK complex lead to GSTPi
aggregate’s formation and JNK activation. Two other papers
have reported that GSTpi is able to S-glutathionylate 1-
Cys-peroxiredoxin (1-Cys-Prx) [69, 70]. 1-Cys-Prx belongs
to the nonselenoperoxidase family and catalyzed the degra-
dation of hydroperoxides to alcohols. The 1-Cys-Prx has a
thioredoxin fold in the N-terminal region where a conserved
cysteine residue is involved in the peroxidase activity. The
oxidized 1-Cys-Prx intermediate must react with another
thiol compound to regenerate the sulfydryl cysteine of
the active 1-Cys-Prx. In their experiments, Ralat et al.
[69] have shown that GSTPi is able to interact with the
oxidized form of 1-Cys-Prx and to re-activate this enzyme
by glutathionylation. This glutathionylation is followed by
the formation of an intermolecular disulfide bond between
the two subunits. Then, the GSH-dependent reduction of the
disulfide regenerates the reduced active-site thiol.
Interestingly, the number of potential S-glutathionylated
protein compared to the proteome is quite low as reported
by Fratelli et al. [7] in hepatocyte after induction of an
oxidative stress. However, more studies are necessary in order
to understand the impact of GSTs on this post-translational
modification and their role in the regulation of signaling
pathway during oxidative stress.
6. GSTs as a NO Carrier
NO is a short-life messenger playing a role in both physio-
logic (by activating the soluble guanylate cyclase) and cyto-
toxic processes (e.g., such as inflammation). Interestingly,
many of these eﬀects are linked to its ability to interact with
Fe(II). In tumor cells, this mechanism resulted in a rapid
diminution of energy and DNA synthesis due to the loss
of iron-containing enzymes. Furthermore, several studies
have shown that interactions with iron-sulfur cluster in
proteins lead to their degradations and to the formation of
dinitrosyl dithiol iron-complexes (DNICs). At physiological
concentration, these complexes are suspected to play the role
of NO carrier, increasing its half life, and suggesting that the
concept of NO as a free diﬀusible compound in cells need to
be reevaluated. Furthermore, recent studies have shown that
MRP1 transporter is able to release these complexes from the
cells [71]. On the other hand, at cytotoxic concentrations,
such as during chronic inflammation, these complexes,
by sequestrating NO, could prevent its cytotoxic eﬀect.
However, when the concentration becomes too important,
the system is overhelmed and a toxicity occurs. For example,
NO is able to bind iron and 2 glutathiones in order to form
the dinitrosyl-diglutathionyl-iron complex (DNDGIC) [8].
This leads to a depletion in glutathion and could represent a
key signal trigerring apoptosis.
Several studies have shown that GSTs could bind DNICs.
Thus GSTA1-1, GSTM1-1 and GSP1-1 are able to bind
DNDGIC in vitro [72]. A crystal structure of the GSTP1-
1-DNDGIC has even been obtained [73]. Tyr-7, in the
active site of the GSTP1-1, coordinated to iron in DNDGIC
displacing one of the GSH. More recently, Lok et al. [74]
have suggested that GSTP1-1 acts to prevent NO-mediated
iron released from MRP1 by sequestring DNICs. Thus a
combinating eﬀect of GSTP1-1 (storage of DNDGIC) and
MRP1 (eﬄux of DNDGIC) seems to play a key role in cell
protection against cytotoxicty.
7. Conclusion
Altogether, these observations clearly demonstrate that GSTs
have roles beyond the simple detoxification reactions and
seat themselves as crucial regulators of the stress kinase
pathways. Among them, the GSTPi may be the most peculiar
GST with its inhibitory role in various signaling pathways
implicated in apoptosis or proliferation. Interestingly, GSTP1
is overexpressed in lung, ovary, pancreas, stomach, and colon
cancers [1] and this high expression level has been correlated
with resistance to several anticancer drugs. [75, 76]. In
the light of the more recent works, interactions of GSTs
with stress kinases could also be involved in such resistance
mechanisms. Recently, Peklak-Scott et al. [77] concluded that
the role of GSTP1-1 in cellular detoxification of cisplatin
failed to totally explain resistance to this drug and that
such mechanism should also involved the modulation of
signaling pathways. Thus, strategies to prevent the apparition
of multidrug resistance should aim at designing specific
inhibitors able to disrupt interactions between GSTs and
protein kinases. This approach has already been done by
several authors [78–80]. However, in order to obtain these
inhibitors, new studies are necessary to define the exact
regions implicated in each interaction. On the other hand,
GSTs role in the metabolism of endogenous compound such
as 4-HNE or 15d-PGJ2 or in the S-glutathionylation of
proteins also indicates that GST levels might be critical in the
control of cell signaling.
These specific functions of GSTs could lead to the
development of new therapeutic approaches and to the
identification of some interesting candidates for preclinical
and clinical development.
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